Halozyme Therapeutics Stock Buy Hold or Sell Recommendation

HALO Stock  USD 62.27  1.21  1.98%   
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Halozyme Therapeutics is 'Strong Buy'. The recommendation algorithm takes into account all of Halozyme Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
  
Check out Halozyme Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.
In addition, we conduct extensive research on individual companies such as Halozyme and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Execute Halozyme Therapeutics Buy or Sell Advice

The Halozyme recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Halozyme Therapeutics. Macroaxis does not own or have any residual interests in Halozyme Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Halozyme Therapeutics' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Halozyme TherapeuticsBuy Halozyme Therapeutics
Strong Buy

Market Performance

SolidDetails

Volatility

Very steadyDetails

Hype Condition

Low keyDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Very SmallDetails

Economic Sensitivity

Slowly supersedes the marketDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

BuyDetails

Financial Strenth (F Score)

HealthyDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Halozyme Therapeutics has a Risk Adjusted Performance of 0.2345, Jensen Alpha of 0.4352, Total Risk Alpha of 0.5695, Sortino Ratio of 0.3593 and Treynor Ratio of 0.8054
Macroaxis provides unbiased trade recommendations on Halozyme Therapeutics that should be used to complement current analysts and expert consensus on Halozyme Therapeutics. Our advice engine determines the entity's potential to grow exclusively from the perspective of an investors' current risk tolerance and investing horizon. To make sure Halozyme Therapeutics is not overpriced, please check out all Halozyme Therapeutics fundamentals, including its current ratio, total asset, and the relationship between the net income and price to earnings to growth . Given that Halozyme Therapeutics has a price to earning of 60.08 X, we strongly advise you to confirm Halozyme Therapeutics market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Halozyme Therapeutics Trading Alerts and Improvement Suggestions

Halozyme Therapeutics is unlikely to experience financial distress in the next 2 years
Over 99.0% of the company shares are owned by institutional investors
Latest headline from finance.yahoo.com: Aperia Announces Exclusive Automatic Tire Inflation Agreement with Goodyear for Tires-as-a-Service Solution with Halo Connect i3

Halozyme Therapeutics Returns Distribution Density

The distribution of Halozyme Therapeutics' historical returns is an attempt to chart the uncertainty of Halozyme Therapeutics' future price movements. The chart of the probability distribution of Halozyme Therapeutics daily returns describes the distribution of returns around its average expected value. We use Halozyme Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Halozyme Therapeutics returns is essential to provide solid investment advice for Halozyme Therapeutics.
Mean Return
0.39
Value At Risk
-1.79
Potential Upside
2.51
Standard Deviation
1.49
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Halozyme Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Halozyme Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument, such as Halozyme Therapeutics, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Halozyme Therapeutics back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
Shares
Dimensional Fund Advisors, Inc.2024-12-31
1.9 M
Goldman Sachs Group Inc2024-12-31
1.9 M
Northern Trust Corp2024-12-31
1.8 M
Charles Schwab Investment Management Inc2024-12-31
1.8 M
Gw&k Investment Management, Llc2024-12-31
1.7 M
Morgan Stanley - Brokerage Accounts2024-12-31
1.6 M
Nuveen Asset Management, Llc2024-12-31
1.5 M
Arrowmark Colorado Holdings, Llc (arrowmark Partners)2024-12-31
1.5 M
Artisan Partners Limited Partnership2024-12-31
1.4 M
Blackrock Inc2024-12-31
17.6 M
Vanguard Group Inc2024-12-31
13.3 M
Note, although Halozyme Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Halozyme Therapeutics Cash Flow Accounts

202020212022202320242025 (projected)
Change In Cash27.5M(29.0M)115.5M(116.3M)(2.5M)(2.4M)
Free Cash Flow53.0M298.0M235.3M373.3M468.4M491.8M
Other Non Cash Items13.6M24.6M9.9M(10.3M)(979K)(930.1K)
Capital Expenditures2.5M1.5M4.8M15.3M10.7M11.2M
Net Income129.1M402.7M202.1M281.6M444.1M466.3M
End Period Cash Flow148.2M119.2M234.7M118.4M115.9M83.8M
Change To Inventory(31.4M)7.4M(17.5M)(26.9M)(67.4M)(64.0M)
Depreciation3.3M3.0M49.6M84.9M81.3M85.4M
Change Receivables(29.4M)(38.3M)6.8M(83.9M)(75.5M)(71.8M)
Change To Netincome36.1M16.4M(113.6M)67.0M60.3M63.3M
Net Borrowings339.0M(19.6M)415.8M617.4M710.1M745.6M
Investments79.8M(404.8M)490.9M(96.9M)(262.7M)(249.6M)

Halozyme Therapeutics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Halozyme Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Halozyme Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Halozyme stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
0.44
β
Beta against Dow Jones0.48
σ
Overall volatility
1.46
Ir
Information ratio 0.33

Halozyme Therapeutics Volatility Alert

Halozyme Therapeutics has relatively low volatility with skewness of 0.64 and kurtosis of 3.61. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Halozyme Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Halozyme Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Halozyme Therapeutics Fundamentals Vs Peers

Comparing Halozyme Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Halozyme Therapeutics' direct or indirect competition across all of the common fundamentals between Halozyme Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Halozyme Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Halozyme Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Halozyme Therapeutics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Halozyme Therapeutics to competition
FundamentalsHalozyme TherapeuticsPeer Average
Return On Equity1.98-0.31
Return On Asset0.18-0.14
Profit Margin0.44 %(1.27) %
Operating Margin0.59 %(5.51) %
Current Valuation8.58 B16.62 B
Shares Outstanding123.15 M571.82 M
Shares Owned By Insiders1.18 %10.09 %
Shares Owned By Institutions98.82 %39.21 %
Number Of Shares Shorted9.22 M4.71 M
Price To Earning60.08 X28.72 X
Price To Book21.07 X9.51 X
Price To Sales7.55 X11.42 X
Revenue1.02 B9.43 B
Gross Profit776.86 M27.38 B
EBITDA656.54 M3.9 B
Net Income444.09 M570.98 M
Cash And Equivalents209.36 M2.7 B
Cash Per Share1.52 X5.01 X
Total Debt1.51 B5.32 B
Debt To Equity4.28 %48.70 %
Current Ratio2.72 X2.16 X
Book Value Per Share2.96 X1.93 K
Cash Flow From Operations479.06 M971.22 M
Short Ratio8.35 X4.00 X
Earnings Per Share3.43 X3.12 X
Price To Earnings To Growth(2.50) X4.89 X
Target Price66.11
Number Of Employees35018.84 K
Beta1.32-0.15
Market Capitalization7.67 B19.03 B
Total Asset2.06 B29.47 B
Retained Earnings359.87 M9.33 B
Working Capital946.24 M1.48 B
Note: Disposition of 71810 shares by Torley Helen of Halozyme Therapeutics subject to Rule 16b-3 [view details]

Halozyme Therapeutics Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Halozyme . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Halozyme Therapeutics Buy or Sell Advice

When is the right time to buy or sell Halozyme Therapeutics? Buying financial instruments such as Halozyme Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Halozyme Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cry Crypto Assets Thematic Idea Now

Cry Crypto Assets
Cry Crypto Assets Theme
An experimental p2p digital currency that is accepted by many vendors in null. The Cry Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cry Crypto Assets Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Halozyme Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Halozyme Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Halozyme Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Halozyme Therapeutics Stock:
Check out Halozyme Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.623
Earnings Share
3.43
Revenue Per Share
8.006
Quarterly Revenue Growth
0.295
Return On Assets
0.1816
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.